Proactive Investors - Run By Investors For Investors

ANGLE: Researchers find new use for company's cancer cell harvesting device

Parsortix was used by a Dusseldorf team called Disseminated Cancer Cell Network
blood in testubes
Parsortix has been developed as liquid biopsy system that captures cancer cells from the blood

Using ANGLE PLC’s (LON:AGL, OTCQX:ANPCY) liquid biopsy has been revealed to result in a 30-fold increase in tumour cells harvested for analysis in cancer patients.

Parsortix was deployed by a Düsseldorf team called Disseminated Cancer Cell Network.

READ: ANGLE technology used in cutting-edge research featured in science journal Nature

The researchers and clinicians were attempting to enhance a technique called diagnostic leukapheresis, which harvests circulating tumour cells (CTCSs) to assess how to better treat patients individually.

The increase in the number of CTCs captured by Parsortix was highly effective in reducing the “background” produced by white blood cells caught during the process.

“The Parsortix system provides an easy solution for enriching the sample and harvesting these CTCs keeping the cells alive and undamaged,” said researcher Dr Hans Neubauer.

“The workflow we have developed to culture these cells will allow an intensification of research into new diagnostic and therapeutic solutions."

The results from the work carried out by the Disseminated Cancer Cell Network were peer-reviewed

and published in the periodical Clinical Chemistry. Click here to read.


View full AGL profile View Profile

ANGLE PLC Timeline

Related Articles

scientists in a lab
January 30 2019
The technology first drew the attention of ChemioCare CEO Pedro Lichtinger years ago while he oversaw Pfizer's global primary care business
September 28 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing
Hep C
November 22 2018
The company made positive operational progress in the year to June 30.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use